Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

opicapone

EU flag

EMA proposes EU clinical trial reforms

The ACT EU paper provides a list of regulatory network objectives, priorities and governance strategies for 2022-2023

- PMLiVE

Amgen’s Lumykras receives conditional marketing authorisation from EC

The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation

Global Marketing, Technology, and Innovation

Jim Lefevere, Director of Global Marketing Services at Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19....

Impetus Digital

- PMLiVE

Roche’s lung cancer combination treatment improves long-term survival

Anti-TIGIT therapy tiragolumab plus Tecentriq offers better progression-free survival improvement after 2.5 years than Tecentriq alone

- PMLiVE

Roche’s Actemra approved for severe COVID-19 in Europe

The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia

- PMLiVE

Roche acquires test maker TIB Molbiol

The Swiss biopharmaceutical group has acquired the Berlin-based diagnostics biotech after two decades of collaboration, expanding its PCR test portfolio

- PMLiVE

Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia

- PMLiVE

UK’s NICE recommends Roche’s Evrysdi

The first oral therapy for the leading genetic cause of death among babies and young children will be available to 1,500 people in England after Roche signed a price-cutting deal

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

New data shows Roche’s Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks

Roche Basel Switzerland

New data for Tecentriq in early-stage lung cancer

Roche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links